Literature DB >> 23434634

Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Amy S Shah1, Lirong Tan, Jason Lu Long, W Sean Davidson.   

Abstract

Recent applications of mass spectrometry technology have dramatically increased our understanding of the proteomic diversity of high density lipoproteins (HDL). Depending on the method of HDL isolation, upwards of 85 proteins have been identified, and the list continues to grow. In addition to proteins consistent with traditionally accepted roles in lipid transport, HDL carries surprising constituents, such as members of the complement pathway, protease inhibitors involved in hemostasis, acute-phase response proteins, immune function mediators, and even metal-binding proteins. This compositional diversity fits well with hundreds of studies demonstrating a wide functional pleiotrophy, including roles in lipid transport, oxidation, inflammation, hemostasis, and immunity. This review summarizes the progression of our understanding of HDL proteomic complexity and points out key experimental observations that reinforce the functional diversity of HDL. The possibility of specific HDL subspecies with distinct functions, the evidence supporting this concept, and some of the best examples of experimentally defined HDL subspecies are also discussed. Finally, key challenges facing the field are highlighted, particularly the need to identify and define the function of HDL subspecies to better inform attempts to pharmacologically manipulate HDL for the benefit of cardiovascular disease and possibly other maladies.

Entities:  

Keywords:  apolipoproteins; complement; function; hemostasis; inflammation; innate immunity; lipid metabolism; mass spectrometry; protease inhibition

Mesh:

Substances:

Year:  2013        PMID: 23434634      PMCID: PMC3770071          DOI: 10.1194/jlr.R035725

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  107 in total

1.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

2.  Fractionation of human serum high density lipoprotein in urea solutions. Evidence for polypeptide heterogeneity.

Authors:  A Scanu; J Toth; C Edelstein; S Koga; E Stiller
Journal:  Biochemistry       Date:  1969-08       Impact factor: 3.162

3.  Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia.

Authors:  Andrew N Hoofnagle; Mingyuan Wu; Albina K Gosmanova; Jessica O Becker; Ellen M Wijsman; John D Brunzell; Steven E Kahn; Robert H Knopp; Timothy J Lyons; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-16       Impact factor: 8.311

4.  Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography.

Authors:  Scott M Gordon; Jingyuan Deng; L Jason Lu; W Sean Davidson
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

5.  Psoriasis alters HDL composition and cholesterol efflux capacity.

Authors:  Michael Holzer; Peter Wolf; Sanja Curcic; Ruth Birner-Gruenberger; Wolfgang Weger; Martin Inzinger; Dalia El-Gamal; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Lipid Res       Date:  2012-05-30       Impact factor: 5.922

6.  Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid.

Authors:  Yan-ling Jiao; Man-Ping Wu
Journal:  Cytokine       Date:  2008-05-22       Impact factor: 3.861

7.  The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain.

Authors:  X Gu; B Trigatti; S Xu; S Acton; J Babitt; M Krieger
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

8.  Distribution of lipids and apolipoproteins in human plasma by vertical spin ultracentrifugation.

Authors:  E Campos; W J McConathy
Journal:  Arch Biochem Biophys       Date:  1986-09       Impact factor: 4.013

9.  Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Authors:  Menno Vergeer; Michiel L Bots; Sander I van Leuven; Dick C Basart; Eric J Sijbrands; Gregory W Evans; Diederick E Grobbee; Frank L Visseren; Anton F Stalenhoef; Erik S Stroes; John J P Kastelein
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

10.  Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

Authors:  Majken K Jensen; Eric B Rimm; Jeremy D Furtado; Frank M Sacks
Journal:  J Am Heart Assoc       Date:  2012-04-24       Impact factor: 5.501

View more
  141 in total

Review 1.  Time to ditch HDL-C as a measure of HDL function?

Authors:  Graziella E Ronsein; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

Review 2.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

3.  Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD.

Authors:  Ling Li; Gurkan Bebek; Stephen F Previs; Jonathan D Smith; Rovshan G Sadygov; Arthur J McCullough; Belinda Willard; Takhar Kasumov
Journal:  J Proteome Res       Date:  2016-08-05       Impact factor: 4.466

4.  Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause.

Authors:  Samar R El Khoudary; Patrick M Hutchins; Karen A Matthews; Maria M Brooks; Trevor J Orchard; Graziella E Ronsein; Jay W Heinecke
Journal:  J Clin Endocrinol Metab       Date:  2016-07-11       Impact factor: 5.958

5.  High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.

Authors:  Ioanna Tiniakou; Elias Drakos; Vaios Sinatkas; Miranda Van Eck; Vassilis I Zannis; Dimitrios Boumpas; Panayotis Verginis; Dimitris Kardassis
Journal:  J Immunol       Date:  2015-04-13       Impact factor: 5.422

Review 6.  Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.

Authors:  Patrick M Hutchins; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

Review 7.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

8.  High-density lipoproteins are a potential therapeutic target for age-related macular degeneration.

Authors:  Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

9.  Apolipoprotein C-III Nanodiscs Studied by Site-Specific Tryptophan Fluorescence.

Authors:  Chase A Brisbois; Jennifer C Lee
Journal:  Biochemistry       Date:  2016-08-23       Impact factor: 3.162

10.  Successful treatment of established heart failure in mice with recombinant HDL (Milano).

Authors:  Joseph Pierre Aboumsallem; Mudit Mishra; Ruhul Amin; Ilayaraja Muthuramu; Herman Kempen; Bart De Geest
Journal:  Br J Pharmacol       Date:  2018-09-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.